<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821664</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH-Nr. 2012-0583</org_study_id>
    <nct_id>NCT01821664</nct_id>
  </id_info>
  <brief_title>Vascular Graft Infections</brief_title>
  <acronym>VASGRA</acronym>
  <official_title>Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schweizerischer Nationalfonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Background: Vascular grafts are increasingly implanted due to an increasing prevalence of&#xD;
      atherosclerosis and diabetes, and about 1-6% of vascular procedures are complicated by&#xD;
      infection. Mortality attributable to prosthetic vascular graft infections (PVGI) is high.&#xD;
      However, there are almost no data regarding best treatment options of such complicated&#xD;
      infections. Most recommendations are based on expert opinion and not on clinical trials or&#xD;
      cohort observational data analyses. Evaluating infectious and other complications after&#xD;
      vascular surgery procedures are important, and additionally, such studies may offer insights&#xD;
      for quality improvement and improved patient outcomes. With the first aim investigators will&#xD;
      establish an infrastructure for studying PVGI in Zurich. Investigators will take advantage of&#xD;
      the Swissvasc registry, a central registry which collects preoperative, operative and&#xD;
      discharge data regarding the index vascular surgical interventions. They will create a&#xD;
      prospective observational cohort database of all patients who receive a vascular graft&#xD;
      (peripheral, aortic, vein) at the University hospital of Zurich (VASGRA Cohort A). Patients&#xD;
      with a PVGI will be included in VASGRA Cohort B and followed up using a flow chart with a&#xD;
      focus on the course of this infectious complication. Additionally, investigators will&#xD;
      establish a biobank with the collection of tissue- and blood samples of patients with PVGI.&#xD;
      With the second aim researchers will investigate different diagnostic, clinical and&#xD;
      therapeutic research questions nested in the VASGRA Cohort. Firstly, they will address&#xD;
      epidemiological questions, such as: determine the incidence and outcome of complications&#xD;
      after vascular graft placement; determine risk factors, best treatment strategies and outcome&#xD;
      of PVGI, and determine the influence of different antibiotic regimens on the outcome of PVGI&#xD;
      due to different bacterial pathogens. Secondly, investigators will determine the accuracy of&#xD;
      different imaging techniques (PET/CT and MRI) for the diagnosis of PVGI, and their individual&#xD;
      role for the assessment of treatment response. Thirdly, investigators will evaluate the&#xD;
      bacterial diversity of vascular wound infections using 16s r-Ribonucleic acid&#xD;
      (RNA)amplification, and investigators will explore whether this bacterial diversity does&#xD;
      predict disease progression. Here, investigators will also study the impact of negative&#xD;
      pressure wound therapy (NPWT) on bacterial diversity in the treatment course of PVGI.&#xD;
      Fourthly, investigators will look for cut-off levels of relevant blood leucocytes count,&#xD;
      C-reactive protein and procalcitonin raising suspicion of a PVGI. Lastly, investigators will&#xD;
      look at histopathological features of excised vascular grafts. Expected value of the project:&#xD;
      Results from the proposed study are an important contribution to the field, based on the&#xD;
      large sample size, longitudinal design and by unifying clinical and epidemiological science.&#xD;
      The very well characterized patient groups and the close connection between vascular&#xD;
      surgeons, infectious disease specialists, specialists in nuclear medicine and microbiologist&#xD;
      will help to investigate PVGI in depths. Investigators hope to be able to develop guidelines&#xD;
      regarding best diagnostic modalities and treatment options in case of vascular graft&#xD;
      infections. In the future we plan to examine bacteria retrieved from the PVGI in the&#xD;
      laboratory in detail. The recovered bacteria will be examined for antimicrobial&#xD;
      susceptibility and their capability to form biofilms. Furthermore investigators will examine&#xD;
      how bacterial recovery form explanted grafts could be optimized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Vascular graft infection</measure>
    <time_frame>within 10 years</time_frame>
    <description>Persons are followed up after vascular graft surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foreign body reaction</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause- mortality</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Prosthetic Vascular Graft Infection</condition>
  <arm_group>
    <arm_group_label>Prosthetic vascular graft implantation, follow up</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prosthetic vascular graft</intervention_name>
    <description>Implantation of a prosthetic vascular graft</description>
    <arm_group_label>Prosthetic vascular graft implantation, follow up</arm_group_label>
    <other_name>Valsalva Graft, Gelwave TM</other_name>
    <other_name>Subclavia Graft, Gelwave TM</other_name>
    <other_name>Longer Ante-Flo Offset branch, Gelwave TM</other_name>
    <other_name>Lupiae Branched Graft, Gelwave TM</other_name>
    <other_name>4 Branched Plexus, Gelwave TM</other_name>
    <other_name>Bifurcate, Gelwave TM soft</other_name>
    <other_name>Subclavia Graft straight, Gelwave TM soft</other_name>
    <other_name>Intergard woven straight, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>Intergard woven hemabridge, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>Intergard woven Aortic Arch, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>Intergard Silver Knitted Bifurcation, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>Intergard Silver Knitted Straight, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>InterGard TM knitted Bifurcation, Intervascular &quot;Maquet Getinge Group&quot;</other_name>
    <other_name>FlowLine Bipore r Heparin ePTFE Vascular Graft, Jotec r GmbH</other_name>
    <other_name>ePTFE Vascular Graft Regular Wall flex, IMPRA r</other_name>
    <other_name>ePTFE Vascular Graft Thin Wall flex, IMPRA r</other_name>
    <other_name>ePTFE Vascular Graft Regular Wall straight, IMPRA r</other_name>
    <other_name>Gore-Tex Stretch Vascular Graft standard Wall Eptfe, W.L. Gore &amp; Associates, Inl</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a vascular surgery at the University hospital will be included in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Control patients:&#xD;
&#xD;
        - Vascular graft surgery (peripheral, aortic, vein)&#xD;
&#xD;
        Case patients:&#xD;
&#xD;
          -  Patients with previous primary implantation of an aortic or peripheral vascular&#xD;
             implant and suspicion of PVGI&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Involvement in a conflicting clinical trial (investigational drug)&#xD;
&#xD;
          -  Inability to follow the procedures of the cohort, e.g. due to language problems,&#xD;
             psychological disorders or dementia of the subject&#xD;
&#xD;
          -  Known or suspected non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Hasse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Hasse, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>barbara.hasse@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prosthetic vascular graft infection</keyword>
  <keyword>negative pressure wound therapy</keyword>
  <keyword>microbiology</keyword>
  <keyword>antimicrobial therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

